Stock Analysis

Top Growth Companies With Insider Ownership In February 2025

KOSDAQ:A298380
Source: Shutterstock

In February 2025, global markets are experiencing a surge with U.S. stock indexes nearing record highs, driven by growth stocks outperforming value shares and the Nasdaq Composite leading gains. Amidst this bullish environment, identifying growth companies with high insider ownership can be particularly appealing as insiders' significant stakes often signal confidence in future prospects and alignment of interests with shareholders.

Top 10 Growth Companies With High Insider Ownership

NameInsider OwnershipEarnings Growth
Archean Chemical Industries (NSEI:ACI)22.9%50.1%
Seojin SystemLtd (KOSDAQ:A178320)32.1%39.9%
Clinuvel Pharmaceuticals (ASX:CUV)10.4%26.2%
SKS Technologies Group (ASX:SKS)29.7%24.8%
Pricol (NSEI:PRICOLLTD)25.4%25.2%
Laopu Gold (SEHK:6181)36.4%38.5%
Plenti Group (ASX:PLT)12.7%120.1%
HANA Micron (KOSDAQ:A067310)18.3%119.4%
Fulin Precision (SZSE:300432)13.6%71%
Findi (ASX:FND)35.8%118.4%

Click here to see the full list of 1466 stocks from our Fast Growing Companies With High Insider Ownership screener.

Let's explore several standout options from the results in the screener.

CLASSYS (KOSDAQ:A214150)

Simply Wall St Growth Rating: ★★★★★★

Overview: CLASSYS Inc. is a global provider of medical aesthetics devices with a market cap of ₩3.71 trillion.

Operations: The company's revenue segment consists of Surgical & Medical Equipment, generating ₩215.54 billion.

Insider Ownership: 13.7%

Return On Equity Forecast: 28% (2027 estimate)

CLASSYS is poised for significant growth with revenue expected to rise 25.5% annually, outpacing the KR market. Earnings are forecast to grow 27.36% per year, supported by a high projected return on equity of 27.8%. Trading at a substantial discount to its estimated fair value, analysts anticipate a price increase of 21.7%. A share buyback program worth KRW 25 billion aims to enhance shareholder value and stabilize stock prices through June 2025.

KOSDAQ:A214150 Ownership Breakdown as at Feb 2025
KOSDAQ:A214150 Ownership Breakdown as at Feb 2025

ABL Bio (KOSDAQ:A298380)

Simply Wall St Growth Rating: ★★★★★☆

Overview: ABL Bio Inc., a biotech research company, specializes in developing therapeutic drugs for immuno-oncology and neurodegenerative diseases, with a market cap of ₩2.26 trillion.

Operations: The company's revenue is primarily derived from its biotechnology startups segment, amounting to ₩32.32 billion.

Insider Ownership: 30.4%

Return On Equity Forecast: N/A (2027 estimate)

ABL Bio is positioned for robust growth, with revenue anticipated to increase 25.5% annually, surpassing the KR market's growth rate. Earnings are projected to expand by 37.98% per year, with profitability expected within three years. Recent shareholder and analyst calls focused on R&D strategies and business plans for 2025, highlighting management's commitment to innovation despite recent share price volatility. Insider ownership remains significant though no recent insider trading activity was reported.

KOSDAQ:A298380 Earnings and Revenue Growth as at Feb 2025
KOSDAQ:A298380 Earnings and Revenue Growth as at Feb 2025

Silergy (TWSE:6415)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Silergy Corp. designs, manufactures, and sells integrated circuit products and related technical services in China and internationally, with a market cap of NT$162.62 billion.

Operations: The company's revenue primarily comes from its semiconductor segment, generating NT$17.63 billion.

Insider Ownership: 14.3%

Return On Equity Forecast: 21% (2027 estimate)

Silergy is poised for significant earnings growth, with forecasts indicating a 40.63% annual increase, outpacing the TW market's 17.9%. Revenue is expected to grow at 20% annually, faster than the market's 11.3%. Despite recent share price volatility and no substantial insider trading activity in the past three months, insider ownership remains high. Recent executive changes include new leadership roles aimed at bolstering strategic direction and corporate governance.

TWSE:6415 Earnings and Revenue Growth as at Feb 2025
TWSE:6415 Earnings and Revenue Growth as at Feb 2025

Summing It All Up

Looking For Alternative Opportunities?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About KOSDAQ:A298380

ABL Bio

A biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases.

High growth potential with excellent balance sheet.